Trial Profile

A Pivotal Phase 2/3 study of ANVS401 in moderate Alzheimer's Disease

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 28 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buntanetap (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Sponsors Annovis Bio

Most Recent Events

22 Mar 2023 According to Annovis media release, company announces presentation from this study at the upcoming AD/PD 2023 International Conference on Alzheimer's and Parkinson Disease which is taking place from 28th March-1st April in Gothenburg, Sweden.
06 Oct 2022 According to an Annovis Bio media release, the U.S. Food and Drug Administration (FDA) has given authorization to initiate this study.
13 Sep 2022 According to an Annovis Bio media release, the company expects to begin this trial later in the year 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com